These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 10993596)
1. Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism. Bengtsson BA Growth Horm IGF Res; 1998 Feb; 8 Suppl A():77-80. PubMed ID: 10993596 [TBL] [Abstract][Full Text] [Related]
2. Growth hormone deficiency in the adult. Doga M; Bonadonna S; Gola M; Mazziotti G; Giustina A Pituitary; 2006; 9(4):305-11. PubMed ID: 17077947 [TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency. Liang S; Xue J; Li G Lipids Health Dis; 2018 Apr; 17(1):66. PubMed ID: 29615058 [TBL] [Abstract][Full Text] [Related]
4. Risk factors of cardiovascular disease in GH-deficient adults with hypopituitarism: a preliminary report. Bohdanowicz-Pawlak A; Szymczak J; Bladowska J; Bednarek-Tupikowska G; Bidzińska B; Milewicz A Med Sci Monit; 2006 Feb; 12(2):CR75-80. PubMed ID: 16449951 [TBL] [Abstract][Full Text] [Related]
9. Replacement therapy and cardiovascular diseases. Boschetti M; Goglia U; Teti C; Esposito D; Giusti M; Minuto F; Ferone D J Endocrinol Invest; 2008 Sep; 31(9 Suppl):85-90. PubMed ID: 19020394 [TBL] [Abstract][Full Text] [Related]
10. Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone replacement therapy in adults with growth hormone deficiency. Boschetti M; Casu M; Moretti S; Teti C; Albanese V; Albertelli M; Murialdo G; Minuto F; Ferone D Hormones (Athens); 2015; 14(1):134-41. PubMed ID: 25402370 [TBL] [Abstract][Full Text] [Related]
11. High incidence of cardiovascular disease and increased prevalence of cardiovascular risk factors in women with hypopituitarism not receiving growth hormone treatment: preliminary results. Erfurth EM; Bülow B; Eskilsson J; Hagmar L Growth Horm IGF Res; 1999 Apr; 9 Suppl A():21-4. PubMed ID: 10429876 [TBL] [Abstract][Full Text] [Related]
12. Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study. Suzuki K; Yanagi K; Shimizu M; Wakamatsu S; Niitani T; Hosonuma S; Sagara M; Aso Y Endocr J; 2018 Jan; 65(1):101-111. PubMed ID: 29070768 [TBL] [Abstract][Full Text] [Related]
13. THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience. Jørgensen JOL; Juul A Eur J Endocrinol; 2018 Jul; 179(1):R47-R56. PubMed ID: 29716978 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk of young growth-hormone-deficient adolescents. Differences in growth-hormone-treated and untreated patients. Lanes R; Paoli M; Carrillo E; Villaroel O; Palacios A Horm Res; 2003; 60(6):291-6. PubMed ID: 14646407 [TBL] [Abstract][Full Text] [Related]
16. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Spielhagen C; Schwahn C; Möller K; Friedrich N; Kohlmann T; Moock J; Kołtowska-Häggström M; Nauck M; Buchfelder M; Wallaschofski H Growth Horm IGF Res; 2011 Feb; 21(1):1-10. PubMed ID: 21093334 [TBL] [Abstract][Full Text] [Related]
18. GH therapy and cancer risk in hypopituitarism: what we know from human studies. Pekic S; Popovic V Eur J Endocrinol; 2013 Nov; 169(5):R89-97. PubMed ID: 23935131 [TBL] [Abstract][Full Text] [Related]
19. Updates in growth hormone treatment and mortality. Sherlock M; Stewart PM Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):314-20. PubMed ID: 23807603 [TBL] [Abstract][Full Text] [Related]